Tag: Oncology Reports
Landmark report in Oncology Reports demonstrates physical accumulation of intravenous Rexin-G nano-medicine within metastatic tumor prior to surgical excision
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G.
